ArticleTranslational cancer research2021
High expression of S100A8 and S100A9 is associated with poor disease-free survival in patients with cancer: a systematic review and meta-analysis.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Diagnostic Value of Synovial Fluid Biomarkers for Periprosthetic Joint Infection: A Prospective, Double-blind Trial.Medical science monitor : international medical journal of experimental and clinical research · 2023Trial
- Targetable S100-RAGE signaling mediates intrinsic trastuzumab deruxtecan resistance in metastatic breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Calprotectin as a Potential Biomarker for Inflammation in Lung Cancer Patients.Diagnostics (Basel, Switzerland) · 2026Article
- Serum S100A8/S100A9 is associated with increased risk of brain metastasis in patients with inflammatory breast cancer.medRxiv : the preprint server for health sciences · 2026Article
- The development of a high-plex spatial proteomic methodology for the characterisation of the head and neck tumour microenvironment.NPJ precision oncology · 2025Article
- ITRAQ and PRM-based quantitative saliva proteomics in gastric cancer: biomarker discovery.Frontiers in molecular biosciences · 2025Article
- Article
- Potential Serum HMGB1, HSP90, and S100A9 as Metastasis Predictive Biomarkers for Cancer Patients and Relevant Cytokines: A Pilot Study.International journal of molecular sciences · 2024Article
- Article
- Architectural organization and molecular profiling of 3D cancer heterospheroids and their application in drug testing.Frontiers in oncology · 2024Article
- S100A8 is a prognostic signature and associated with immune response in diffuse large B-cell lymphoma.Frontiers in oncology · 2024Article
- Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia.Blood cancer journal · 2023Article
- Article
- The functions and regulatory pathways of S100A8/A9 and its receptors in cancers.Frontiers in pharmacology · 2023Review
- LOXL1 and LOXL4 are novel target genes of the ZnFrontiers in oncology · 2023Article
- Ivermectin Affects Neutrophil-Induced Inflammation through Inhibition of Hydroxylysine but Stimulation of Cathepsin G and Phenylalanine Secretion.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe expression of S100A8 and S100A9 is found to be related with the survival of cancer patients, but the results and information regarding their prognostic significance are inconsistent in literature. This study, therefore, aimed to perform a comprehensive meta-analysis and determine the prognostic significance of S100A8 and S100A9 expression in patients with cancer.
methodsData were collected by performing a literature search on the PubMed, Cochrane library, and Scopus databases. Pooled hazard ratio (HR) with confidence interval (CI) was calculated to assess the correlation between S100A8 and S100A9 expression and survival in patients with cancer.
resultsIn total, 5 studies that enrolled 735 cancer patients were included in the meta-analysis. The pooled HR concerning S100A8 and S100A9 expression was 1.98 (95% CI: 1.20-3.29, P=0.008) for disease-free survival (DFS), indicating an association between high expression of S100A8 and S100A9 and poor DFS in cancer patients. However, the expression of S100A8 and S100A9 was not significantly correlated with disease-specific survival (HR 1.71, 95% CI: 0.86-3.40, P=0.128). DISCUSSION: The current meta-analysis revealed that S100A8 and S100A9 expression may be a potential prognosticator of DFS in cancer patients. The present systematic review is the first to investigate the survival outcomes of cancer patients with S100A8 and S100A9 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.